Revelation Biosciences (REVB) announced that dosing has been completed for the PRIME Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease. A total of five cohorts were enrolled at three clinics in the U.S. The company expects to share study data, including safety parameters and biomarkers of activity, during Q3 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REVB:
- Revelation Biosciences Announces Reverse Stock Split
- Upcoming Stock Splits This Week (July 7 to July 11) – Stay Invested
- Revelation Biosciences Inc trading halted, news pending
- Revelation Biosciences announces 1-for-3 reverse stock split, effective July 7
- Revelation Biosciences Holds Annual Meeting with Key Votes